2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2258

Causes of Influenza Vaccine Hesitancy in Rheumatoid Arthritis and Adults with Juvenile Idiopathic Arthritis
Abstract Number: 1764

CCL25, a Novel Fibroblast and Macrophage Chemoattractant That Potentiates RA Bone Erosion
Abstract Number: 1987

CCN3 Regulates Macrophage Function in MSU-induced Inflammation
Abstract Number: 687

CCP Autoantibody Positive SLE Patients Show Unique Enrichments in SLE Criteria and Autoantibody Biomarkers That Vary by Race
Abstract Number: 1072

CCR2+ Circulating Monocytes Contribute to the Survival of ADSC in Bleomycin-Induced Skin Fibrosis
Abstract Number: 1064

CD123+ Plasmacytoid Dendritic Cells from Systemic Sclerosis Patients Are Susceptible to the Cytotoxic Activity of Tagraxofusp, a CD123-Targeted Therapy
Abstract Number: 101

CD126 Negative CD4+Foxp3+ Cell Represents a Superior Treg Subset in Treating Autoimmune Diseases
Abstract Number: 1971

CD39 Produced from Human Gingiva-Derived Mesenchymal Stem Cells Regulates the Balance of Osteoclasts and Osteoblasts Through Wnt / β-catenin Pathway in Osteoporosis
Abstract Number: 1069

CD4+ T Helper Cell Populations with High PD-1 Expression Are Expanded in Systemic Sclerosis
Abstract Number: 65

CD6 Modulation Ameliorates Skin and Kidney Disease in a Spontaneous Murine Model of SLE
Abstract Number: 2894

CD6-ALCAM Signaling Is Upregulated in Kidneys with Lupus Nephritis and Is Associated with Disease Activity
Abstract Number: 115

CD8+ Cytotoxic T Lymphocytes Are Clonally-expanded in IgG4-related Disease and Home to Affected Tissues
Abstract Number: 1403

CDAI Analysis of Dose Escalation in a Trial of Infliximab for Rheumatoid Arthritis
Abstract Number: 2887

Cell-bound Complement Activation Products in Combination with Low Complement C3 or C4 Have Superior Diagnostic Performance in Systemic Lupus Erythematosus
Abstract Number: 2626

Cell-free Mitochondrial DNA Levels in Granulomatosis with Polyangiitis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].